cgt europe 2015 post event report
TRANSCRIPT
29-30 SEPTEMBER 2015 | THE MAJESTIC HOTEL, BARCELONA
POST EVENT REPORT
CELL & GENE THERAPY EUROPE
127Organisations
20Countries
220+Attendees
75Speakers
73%Director
and above
Silver sponsors Bronze sponsors
THANKS TO OUR SPONSORS
WWW.CGTEUROPE.COM
Gold Sponsor
"We've met a lot of new companies and made alot of new contacts. We are dealing with a globalindustry now. We have found it hugely beneficialand will definitely be coming again."Robert Jones, General Manager, Fisher Bioservices
WWW.CGTEUROPE.COM
EXPERT SPEAKERS AT THE EVENT INCLUDED
MISSED CELL &GENE THERAPY
EUROPE?
SEE ALL THE ACTION FROMTHE EVENT ONLINE HERE
“It was a very interesting event as allparticipants, including speakers wereready to exchange, even on the mostchallenging subjects such asreimbursement, GMP guidance.”Bertrand Alexandre, Director, MarketingEurope, Celyad
“Real forward-thinking combiningexperts in the field from manufacturing,regulatory and value vision” – “greatnetwork with strong experience andsharing risks & opportunities” Jean-Philippe Combol, Chief OperatingOfficer, GenSight Biologics
"I want to reinforce the comments youhave received that the Conference inBarcelona was excellent in content,interactions and atmosphere.”Dr Carlos Plata, Chief Scientific Officer, ChiefMedical Officer & Head of R&D, Esteve
Dr Ruxandra Draghia-Akli, Director, HealthDictorate, Research &Innovation DG,European Commission
Michael Covington,Principal CMCRegulatory Affairs Policy& Strategy, Juno
Dr Christian Meyer,Chief Medical Officer,uniQure
Dr Marcos Timon,Head of Service,AEMPS; Member,Committee forAdvanced Therapies(CAT)
Dr Kush Parmar,Partner, 5AM Ventures
Edward Lanphier, President & ChiefExecutive Officer,Sangamo BioSciencesInc; Chairman,Alliance ofRegenerativeMedicine (ARM)
Dr Leeza Osipenko,Associate Director, NICEScientific Advice,National Institute forHealth & CareExcellence (NICE)
Dr Francois Meyer, Advisor to the President,International Affairs,Haute Autorité deSanté (HAS)
Dr Fatiha Sadallah, Principal ScientificManager, Innovative MedicinesInitiative
Prof. Chris Mason,Chair of RegenerativeMedicine Bioprocessing,University CollegeLondon
Ajan Reginald, Chief Executive Officer, Cell therapy Limited
Dr Maria Cristina Galli, Co-chair of the ATMPplatform, EATRIS-ERIC, the EuropeanInfrastructure forTranslationalMedicine; Departmentof Cell Biology andNeurosciences,Istituto Superiore diSanità
Dr Joern-Peter Halle, Senior Vice President,Global Head of ExternalInnovation, Merck Serono
Dr Maria Pascual,VP Regulatory Affairs &Corporate Quality,TiGenix
Dr Sven Kili,Vice President & Head ofGene TherapyDevelopment,GlaxoSmithKline
Jan Thirkettle,Vice President, Cell &Gene Therapy ProductDevelopment & Supply,Platform Technology &Sciences,GlaxoSmithKline
Lennart Åkerblom, Senior Expert, MedicalProducts Agency(MPA) Sweden &Member, Committeefor AdvancedTherapies (CAT)
Dr Anton Simeonov,Acting Deputy ScientificDirector, NationalCentre for AdvancingTranslational Sciences(NCATS), NIH
Andrea Chiesi,Director, R&D PortfolioManagement, ChiesiFarmaceutici SpA; Co-Founder & ChiefExecutive Officer,Holostem
Dr Ralf Sanzenbacher,Deputy Head of Section,Tissue-Engineering &Cell Therapeutics, Paul-Ehrlich-Institut,Federal Institute forVaccines andBiomedicinesGermany
� Head of Global Medical Affairs &EU Clinical Development
� Vice President & Head of GeneTherapy Development
� Senior Vice President, Clinical &Regulatory
� Vice President, Manufacturing� Vice President, Cell & GeneTherapy Product Development& Supply
� Senior Director, Scientific Affairs& Analysis
� Global Head of ClinicalDevelopment
� Chief Executive Officer� Chief Medical Officer� Chief Regulatory & ComplianceOfficer
31% Vendors7%Regulators
4% VCs4%Academics
54%Phama/Biotech
SENIORITY LEVEL
ORGANISATIONTYPE
AUDIENCE PROFILE
ATTENDING COMPANIES INCLUDED
JOB TITLES INCLUDED
WWW.CGTEUROPE.COM
"The conference consistently proves to be a great forum fornetworking with industry leaders in the development ofcellular and gene therapies as well as vendors for importanttechnologies and services.”Michael Covington, Principal CMC Regulatory Affairs Policy &Strategy, Juno Therapeutics, Inc
“Indeed, I found the meeting outstanding and have nonegative points (quite unusual for a regulator). Thank you foryour outstanding organizational support.”Dr Ralf Sanzenbacher, Deputy Head of Section, Tissue-Engineering & CellTherapeutics, Paul-Ehrlich-Institut, Federal Institute for Vaccines andBiomedicines Germany
73%Director level and above
17%Manager level
10% Academics / Scientists
REQUESTTHE FULL
ATTENDANCELIST HERE
REGISTRATION
MEETING VILLAGE
21
25 31
14
15
1617
1819
23
24
1
2
3
4
5
67
8 910 11
12 13
2827
26
30
20
21 - 22 SEPTEMBER 2016 | THE MARITIM HOTEL, BERLIN
IMMUNOTHERAPY EUROPE
CELL & GENETHERAPY EUROPE
Following the sell-out success ofCell & Gene Therapy Europe 2015,Phacilitate will be launchingImmunotherapy Europe alongsidethe 2016 edition of Cell & GeneTherapy Europe.
Join us and hundreds of cell, geneand immunotherapy executives inBerlin. Contact [email protected] or on +44 (0)207 384 7951 to findout how.
SPONSORS ALREADY CONFIRMED
JOIN US IN WASHINGTON 25 - 27 JANUARY 2016!Don’t miss the next edition of Cell & Gene Therapy World when it returns toWashington DC this January. With even more content streams, exciting new
features and an even larger audience to network and collaborate with, you can’tafford to miss the world’s premier cell and gene therapy event.
Find out more at www.bioleaders-forum.com now
CONTACT US
SPONSORSHIP ENQUIRIES:Michael AdeniyaBusiness DevelopmentDirectorE: [email protected]: +44 (0)207 384 7951
DELEGATE ENQUIRIES:Kim EvansSenior Programme ManagerE: [email protected]: +44 (0)207 384 7993
CONTENT & OVERALL EVENTENQUIRIES:James McGoughPortfolio DirectorE: [email protected]: +44 (0)207 384 7971
MEDIA & MARKETINGENQUIRIES:Carina HunterMarketing ManagerE: [email protected]: +44 (0)207 384 7897
NEXT YEAR'S DATES CONFIRMED! SIGN UP NOW FOR BERLIN 2016!